Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.70 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SNCA | P37840 | 1/20 | 0.65 |
| ▸ | STAT3 | P40763 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.60 |
| ▸ | PIP4K2C | Q8TBX8 | 3/20 | 0.59 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22263287 | 1.00 | CRBN (0.70) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL17873780 | 1.00 | CRBN (0.70) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL23884363 | 0.99 | CRBN (0.71) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL26319140 | 0.97 | CRBN (0.72) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL26317549 | 0.97 | CRBN (0.72) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL17839764 | 0.96 | CRBN (0.69) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL26317544 | 0.96 | CRBN (0.73) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL17873761 | 0.95 | CRBN (0.70) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL29558168 | 0.94 | CRBN (0.74) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL24418639 | 0.94 | CRBN (0.74) | CRBNDDB1HDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3676268-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | Dana-Farber Cancer Institute, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019079701-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885HDAC1 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.